Fortis Healthcare has announced an ambitious expansion strategy that will significantly enhance its healthcare infrastructure across India. The company's comprehensive growth plan demonstrates its commitment to strengthening its position in the competitive healthcare sector.

Expansion Strategy and Capacity Enhancement

The healthcare provider has outlined plans for aggressive expansion, targeting the addition of over 3,200 beds by 2030. This substantial capacity increase represents a major milestone in the company's growth trajectory and reflects its confidence in the expanding healthcare market in India.

Strategic Acquisitions and Geographic Expansion

As part of its expansion roadmap, Fortis Healthcare is making strategic acquisitions in key markets including Bangalore and Punjab. These acquisitions are expected to strengthen the company's presence in these important healthcare markets and provide enhanced access to quality healthcare services for patients in these regions.

Corporate Developments and Financial Milestones

The company has successfully completed the closure of the IHH Open Offer, marking an important corporate milestone. This development provides clarity on the company's ownership structure and strategic direction moving forward.

Operational Performance and Medical Tourism Growth

Fortis Healthcare is experiencing positive momentum across several key operational metrics. The company is witnessing growth in medical tourism, indicating increased confidence from international patients seeking quality healthcare services. Additionally, the organization is reporting improvements in Average Revenue Per Occupied Bed (ARPOB) and occupancy rates, reflecting enhanced operational efficiency and patient demand.

Diagnostic Services Focus

The company is placing increased emphasis on its diagnostic B2C segment, recognizing the growing demand for direct-to-consumer diagnostic services. This strategic focus aligns with evolving patient preferences and the increasing importance of preventive healthcare in the Indian market.

Fortis Healthcare has received a credit rating reaffirmation from CRISIL Ratings, maintaining its strong financial standing in the healthcare sector. The rating agency has reaffirmed the company's ratings at 'CRISIL AA+/Stable/CRISIL A1+' for both bank facilities and non-convertible debentures, reflecting the healthcare giant's robust operational performance and strategic market position.

GST Order Against Subsidiary

Fortis Health Management Limited, a wholly-owned subsidiary of Fortis Healthcare, has received a significant GST order from Tamil Nadu tax authorities. The State Tax Officer (ST)- Group IX, Chengalpattu Intelligence Division has confirmed a demand against the subsidiary:

The order, received on January 02, 2026, relates to the denial of GST exemption claims for healthcare services. The original show cause notice was issued for ₹570.00 lakhs including penalty of ₹285.00 lakhs for fiscal year 2023-24.

Company's Response and Legal Position

Fortis Healthcare has indicated its intention to challenge the GST order through appropriate legal channels:

The company maintains that based on its assessment, the demand is not sustainable and does not expect any material impact on its financial performance, operations, or other business activities.

Rating Details and Scope

The CRISIL reaffirmation covers substantial financial instruments across Fortis Healthcare's portfolio:

The rating action builds upon the previous upgrade when CRISIL elevated the long-term ratings from 'CRISIL AA/Stable' to 'CRISIL AA+/Stable' while maintaining the short-term rating at 'CRISIL A1+'.

Strong Operational Performance

Fortis Healthcare demonstrated impressive financial growth during the first half of fiscal 2026:

Market Position and Infrastructure

Fortis Healthcare maintains its position as one of India's largest hospital chains with an extensive network:

Financial Health and Growth Strategy

CRISIL's assessment highlights Fortis Healthcare's healthy financial risk profile:

The company's liquidity position remains strong with ₹413 crores in cash and cash equivalents, and expected net cash accrual of ₹1,200-1,400 crores annually over fiscals 2026-2028.